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Objective: In humans, a single exposure to phencyclidine (PCP) can induce a schizophrenia-like psychosis which can persist 
for up to two weeks. In rats, an acute dose of PCP increases dopaminergic activity and causes changes in dopamine related 
behaviours some of which are sexually dimorphic. To better understand the effects of PCP on dopamine receptor adaptations 
in the short term we examined dopamine D1-like receptors (D1R) and D2-like receptors (D2R) in the mesolimbic and nigrostriatal 
dopamine pathways, 4 hours after exposure to PCP in female rats. 
Methods: Animals received a single dose of 40 mg/kg PCP and were sacrificed 4 hours later. In vitro autoradiography was 
carried out using [3H] SCH 23390 and [3H] raclopride that target D1R and D2R respectively, in cryostat brain sections. 
Results: Two way analysis of variance (ANOVA), revealed an overall effect of PCP treatment (F [1,63]=9.065; p=0.004) on D1R 
binding with an 18% decrease (p＜0.01) in binding in the medial caudate putamen. PCP treatment also had an overall effect 
on D2R binding (F [1,47]=5.450; p=0.024) and a trend for an increase in D2R binding across all the brain regions examined. 
Conclusion: These results suggest opposing D1R and D2R adaptations in striatal subregions of female rats following acute ex-
posure to PCP that may occur through indirect mechanisms.
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INTRODUCTION
　Phencyclidine (PCP) is an N-methyl-D-aspartate (NM-
DA) receptor antagonist that was first developed as an an-
aesthetic but is now a widely abused street drug.1,2) It in-
duces a schizophrenia-like syndrome in normal in-
dividuals and a single exposure to PCP can lead to psy-
chosis in humans lasting up to two weeks.3,4) PCP has 
proved a valuable resource for modelling behaviours rele-
vant to some symptoms of schizophrenia in laboratory 
animals. Understanding the neurochemical alterations un-
derlying the behavioural changes that take place follow-
ing PCP exposure may therefore have possible relevance 
to the pathophysiology associated with psychosis and 
schizophrenia.
　In rodents, a single dose of PCP induces a range of dop-
amine related behaviours such as hyperlocomotion, cata-
leptic freeze, stereotyped behaviour and deficits in the 
sensory gating measure- prepulse inhibition.5-10) It also in-
duces deficits in learning and memory in the rat, cat and 
rhesus monkey.1,11) In rats treated with various doses of 
PCP (19.5, 32.6, 54.4 mg/kg), stereotypy and cataleptic 
freeze has been shown to reoccur for up to 21 days after 
the single dose administration.6)
　PCP is thought to act as an indirect agonist of dopamine 
and alterations in the dopaminergic system are thought to 
be one of the underlying neurochemical substrates for 
PCP induced behaviour.2,8) Indeed, PCP treatment has 
been shown to increase levels of dopamine and its metabo-
lites such as DOPAC and HVA, in the striatum, nucleus ac-
cumbens and medial prefrontal cortex in the rodent7,9,12,13) 
and primate brain.12) In addition, PCP induced behaviours 
can be attenuated or blocked by a range of D1 and D2 dop-
amine receptor antagonists.10,14-16) Few studies however 
have examined short term changes that occur in dopamine 
receptor systems following PCP exposure particularly in 
the female rat brain17) despite reported sexual dimorphism 
in some metabolic and behavioural responses to PCP 
treatment.18-20) 
　In the current study, we investigated whether rapid al-
terations occur in dopamine receptors shortly after PCP 
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exposure, in female rats. We examined brain regions tar-
geted by the mesolimbic dopamine pathway (ventral teg-
mental area to accumbens and olfactory tubercle) since 
dysregulation of dopamine in these regions is believed to 
lead to psychosis, particularly the positive symptoms of 
schizophrenia.21) We also looked at brain regions that are 
targeted by the nigrostriatal pathway (substania nigra to 
striatum), which is important in the control of movement 
and locomotion that are affected by PCP.6) In vitro auto-
radiography was carried out using [3H] SCH 23390 and 
[3H] raclopride to examine dopamine D1-like receptor 
(D1R) and D2-like receptor (D2R) binding respectively, 4 
hours after a single administration of PCP.
METHODS
Animals and PCP Treatment
　All experiments were carried out in accordance with the 
University of Wollongong Animal Care Ethics Commi-
ttee guidelines, which follow the National Health and 
Medical Research Council guidelines for animal expe-
rimentation. All efforts were made to minimise animal 
suffering. Female Sprague-Dawley rats (228-270 g) were 
obtained from the Animal Resources Centre (Perth, WA, 
Australia). The animals were kept at a constant temper-
ature of 22±2oC on a 12-12 h light-dark cycle and were al-
lowed 1 week to acclimatise prior to the experiment. Food 
and water were freely available. The day of PCP treat-
ment, rats were randomised and divided into one control 
group that received saline vehicle and one treated group 
that received PCP (40 mg/kg, i.p.). Both groups were de-
capitated under carbon dioxide anaesthesia 4 h post 
injection. Brains were removed and frozen in isopentane. 
Coronal brain sections (20μm) were cut with a cryostat 
and thaw mounted onto gelatinised microscope slides. 
Consecutive sections (six per slide) were taken from two 
brain compartments corresponding to plates 12-15 and 
28-35 from a standard brain atlas.22)
In vitro Autoradiography
　Experiments were conducted using a single saturating 
concentration of the radioligands, approximately 2-3 
times the Kd, (Kds for [3H]SCH23390 and [3H] raclopride 
1 nM23)and 1.05 nM24) respectively) which gives a good 
approximation of radioligand binding sites in tissue sec-
tions.25) D1 receptor binding was carried out according to 
established methods4,26) with minor modifications. Slides 
were preincubated for 10 min at room temperature in a 
buffer containing 120 mM NaCl, 5 mM KCl, 2.5 mM 
CaCl2, 1 mM MgCl2, 50 mM Tris HCl (pH 7.4). Sections 
were incubated in the same buffer with the addition of 2-3 
nM [3H] SCH 23390 (specific activity 85.0 Ci/mmol, 
Perkin Elmer, USA) and 5μM ketanserin for 60 min at 
room temperature. Non-specific binding was determined 
by incubating adjacent sections in the same incubation 
solution in the presence of 10μM SKF 38393. Sections 
were then washed twice in ice cold buffer for 1 min fol-
lowed by a dip in ice cold distilled water and dried.
　The procedure for D2 receptor binding was performed 
according to established protocols26-28) with minor modi-
fications. Slides were pre-incubated at room temperature 
for 20 min in a buffer containing 120 mM NaCl, 2 mM 
CaCl2, 1 mM MgCl2, 50 mM Tris HCl (pH 7.4). Sections 
were then incubated in the same buffer with the addition of 
3-4 nM [3H] raclopride (specific activity 62.2 Ci/mmol, 
Perkin Elmer, USA) for 60 min at room temperature in the 
absence or presence of 10 µM butaclamol to determine the 
total and the non-specific binding respectively. Post in-
cubation, sections were washed (2×5 min) in ice cold buf-
fer and dipped in ice-cold distilled water and then dried.
　Following the assay, dried sections were apposed to 
Kodak Biomax MR film, together with autoradiographic 
standards ([3H] microscales from Amersham), in x-ray 
film cassettes. Films were exposed for 36 and 70 days for 
[3H] SCH 23390 and [3H] raclopride respectively. Films 
were then developed using Kodak GBX developer and 
fixed with Kodak GBX fixer.
Quantitative Analysis of Autoradiographic Images
　All films were analyzed by using a computer-assisted 
image analysis system, Multi-Analyst, connected to a 
GS-690 Imaging Densitometer (Bio-Rad, USA). As de-
tailed in Fig. 1, brain regions quantified included the later-
al and medial caudate putamen, nucleus accumbens and 
the olfactory tubercle. [3H] SCH 23390 binding was also 
quantified in the substantia nigra (Fig. 2). Quantification 
of receptor binding in each brain region was performed by 
measuring the average optical density in six adjacent brain 
sections (three for the total binding and three for the 
non-specific binding). Non-specific binding was sub-
tracted from the total binding to determine the specific 
binding. Optical density measurements for specific bind-
ing were then converted into fmoles [3H] SCH 23390 or 
[3H] raclopride per mg tissue equivalent (fmol/mg TE), 
according to the calibration curve obtained from the tri-
tium standards.
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Fig. 1. Typical autoradiographs 
showing binding of the D1 and D2 
receptor ligands, [3H] SCH 23390 
and [3H] raclopride respectively in 
control and PCP treated female 
rats. Line diagram showing brain 
regions is adapted from Paxinos 
and Watson (1997). PCP, phen-
cyclidine; ACB, nucleus accum-
bens; CPUL, lateral caudate put-
amen; CPUM, medial caudate put-
amen; TU, olfactory tubercle nu-
cleus.
Fig. 3. [3H] raclopride binding in fmoles/mg tissue equivalent (TE) in 
female rats treated with vehicle or PCP. *Statistically significant 
effect of treatment revealed by two way ANOVA (F (1, 47)=5.450, 
p=0.024). See Fig. 1 for abbreviations.
Fig. 2. [3H] SCH 23390 binding in fmoles/mg tissue equivalent (TE) in 
female rats treated with vehicle or PCP. *p＜0.01 in LSD post hoc 
tests (n=5-7 per group) after two way ANOVA (treatment x region). 
SNR, substantia nigra. See Fig. 1 for other abbreviations.
Statistical Analysis
　[3H] SCH 23390 or [3H] raclopride binding densities 
were analysed for significant population outliers (±2 SD). 
Two way analysis of variance (ANOVA) was carried out 
to identify statistically significant variation in radioligand 
binding with treatment status (PCP treated versus con-
trols) and brain regions as factors. LSD post hoc tests were 
performed to compare binding within the various brain re-
gions examined. Data was analyzed using the PASW 
Statistics 18.0 for Windows (IL, USA). Differences were 
regarded as statistically significant if p＜0.05.
RESULTS
　Two way ANOVA revealed a statistically significant 
overall variation in [3H] SCH 23390 binding with PCP 
treatment (F [1, 63]=9.065, p=0.004) and brain region (F 
[4, 63]=30.323, p＜0.0001). A significant interaction be-
tween these two variables was not found. Post hoc tests re-
vealed a statistically significant 18% (p=0.008) decrease 
in [3H] SCH 23390 binding in the medial caudate putamen 
(Fig. 1, 2). The decrease in [3H] SCH 23390 binding in the 
nucleus accumbens (15%) also approached significance 
(p=0.055).
　Statistical analysis revealed significant variation in 
[3H] raclopride binding with treatment (F [1, 47]=5.450, 
p=0.024) and brain region (F [3, 47]=64.307, p<0.0001). 
A significant interaction between treatment and region 
was not found. Post hoc tests did not detect any statisti-
cally significant individual changes in binding in brain 
region or treatment group (Fig. 1, 3) although the in-
crease in the lateral caudate putamen approached sig-
nificance (p=0.086). These results indicate that non-sig-
nificant increases in [3H] raclopride binding (medial cau-
date putamen=0.75%; lateral caudate putamen=10%; nu-
cleus accumbens=13%; olfactory tubercle=15%) oc-
curred in the regions assessed in PCP treated rats com-
pared to controls, the sum of these changes resulting in the 
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significant, region-wide effect of PCP treatment on [3H] 
raclopride binding.29)
DISCUSSION
　The main findings of the current study are that acute 
treatment with PCP is associated with 18% decrease in 
D1R binding in the medial caudate putamen and a sig-
nificant overall increase in D2R binding in the female rat 
brain, 4 hours after exposure.
　Our results are in agreement with a previous study con-
ducted in male rats in which D1R and D2R levels were ex-
amined in the 2 hour period after exposure to PCP.17) 
Tomić et al.17) reported decreases following PCP treat-
ment in [3H] SCH 23390 binding of 25% and 33% in the 
striatum and nucleus accumbens. Using the D2R antago-
nist, [3H] spiperone, they also reported an increase in D2R 
binding in the striatum. Despite sexual dimorphism re-
ported for some of the metabolic19) and behavioural ef-
fects of PCP18,19) it appears that the effects of acute PCP 
treatment on dopamine receptor binding density are sim-
ilar in the male17) and female rat brain (our study).
　The changes in dopamine receptor binding levels ob-
served in the current study reflect opposing D1R and D2R 
adaptive responses to receptor stimulation.3) PCP is 
thought to act as an indirect agonist of dopamine.2,8) D1Rs 
are postsynaptically located where their activation gen-
erally leads to an excitatory neuronal response.30,31) The 
significant decrease in D1R levels observed in the medial 
caudate putamen accompanied by non-significant de-
creases in the lateral caudate putamen and accumbens fol-
lowing acute PCP treatment probably reflects an adaptive 
downregulation in response to a drug-induced increase in 
dopamine levels in these regions.3,7,9,12,13) This inter-
pretation should however be treated with caution as an in 
vivo study in rats reported decreased [3H] SCH 23390 
binding in the striatum following dopamine depletion.32) 
In addition Kobayashi and Inoue33) looking at the acute ef-
fects of MK-801 (another NMDA receptor antagonist) in 
male mice using vivo administration of [3H] SCH 23390 
(via the tale vein) in combination with ex vivo liquid scin-
tillation detection, reported increased striatal [3H] SCH 
23390 binding.33)
　D2Rs are not only postsynaptically located like D1Rs 
but they are also found on dopamine cell bodies where 
they act as autoreceptors regulating the firing rate of DA 
neurons.31) As mentioned above, PCP increases levels of 
dopamine in the brain therefore the increase in D2R levels 
observed in the current study may reflect a compensatory 
upregulation of the D2 autoreceptor in order to counteract 
the dopaminergic hyperactivity induced by PCP treat-
ment.31) In contrast to our study however an in vivo PET 
imaging study in female baboons reported small decreases 
in [11C]raclopride binding in the striatum after a range of 
doses of PCP.34) The discrepancies between our study and  
results reported in the literature for both D1R and D2R 
binding may reflect methodological differences, type and 
dose of antagonist used as well as species or gender 
differences. More detailed observations on the effects of 
NMDA receptor antagonism on brain dopamine receptors 
and how they are affected by dose, animal species or gen-
der, are required to reach a consensus.
　In the same cohort of animals used is this study, pre-
viously we have shown that acute exposure to PCP is asso-
ciated with a marked decrease in AMPA receptor levels in 
cortical and limbic brain regions35) suggesting that PCP 
produces a prominent disruption of glutamatergic func-
tion in these regions. It is possible that acute changes in 
AMPA and dopamine receptors levels after PCP treatment 
are related since it has been shown that AMPA receptor ac-
tivity influences dopamine release in the nucleus acc-
umbens.36)
　Interestingly, the adaptive responses induced by acute 
PCP exposure observed in the current study mirror some 
changes that are observed in dopamine receptor levels in 
schizophrenic patients. PET and SPECT studies for exam-
ple have revealed that schizophrenic patients show a 
10-20% elevation in the density of the D2R (one of the 
main targets for antipsychotic drugs) in the striatum com-
pared to controls, independent of the effects of antipsy-
chotics.37) Alterations in D1R levels are also associated 
with cognitive impairments and negative symptoms in 
schizophrenia.37) The results of imaging studies however 
are still inconclusive with reports of reduced, unchanged 
and elevated D1R levels from various studies.37)
　Our findings indicate that rapid changes occur in the 
dopaminergic system in the female rat brain following 
acute PCP exposure and may help to elucidate the under-
lying mechanisms by which a single PCP exposure causes 
psychotic symptoms in normal individuals. Based on our 
findings and those of Tomić et al.,17) the acute effects of 
PCP on D1R and D2R binding are similar in male and fe-
male rats.
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